Ozempic and Mounjaro on the PBS: what's actually being proposed

What did @7newsaustralia actually say?

The claim is straightforward: injectable GLP-1 drugs like semaglutide and tirzepatide could soon be subsidised for Australians without type 2 diabetes, after Health Minister Mark Butler confirmed the government is actively considering PBS listing. The report puts the number of current users at "around half a million Aussies" and frames PBS inclusion as something that could happen "as soon as next year."

That framing deserves some scrutiny. "Considering" is not a timeline. And the gap between a minister flagging a policy review and a drug actually appearing on the PBS schedule is often measured in years, not months. Still, the core information here is factually grounded, even if the tone leans optimistic.

Does the science back this up?

The clinical case for PBS listing is genuinely strong, and the evidence base here is not ambiguous. Yes, these drugs work for weight loss in people without type 2 diabetes. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks in adults with obesity but without diabetes. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide produced up to 22.5% weight reduction in the same population.

These are not trivial numbers. The Therapeutic Goods Administration has already approved Wegovy (semaglutide 2.4mg) for chronic weight management in Australia. The pharmacology is real. The question for the PBS is not whether the drugs work, but whether the cost-effectiveness modelling justifies public subsidy, which is a separate and genuinely complicated calculation.

What did they get wrong (or right)?

Two things worth flagging. First, the mispronunciations: "Zempic" and "Monjaro" instead of Ozempic and Mounjaro. This sounds minor but matters in health reporting. People searching for these medications may not find accurate information if names are garbled, and in a video with 1.4 million views, that compounds fast.

Second, the "half a million Aussies" figure. This number has been cited in Australian media but its sourcing is murky. It likely combines both PBS-subsidised prescriptions (type 2 diabetes patients on Ozempic) and private prescriptions. The Pharmacy Guild and some market research firms have floated similar estimates, but there is no published peer-reviewed figure confirming this. It may be accurate, but it should be treated as an estimate, not a hard count.

What they got right: the current PBS eligibility restriction to type 2 diabetes is accurate. Ozempic (semaglutide 1mg) is PBS-listed for type 2 diabetes management. Wegovy is not PBS-listed. Anyone using these drugs for weight loss alone is currently paying full private price, which can exceed $400 per month.

What should you actually know?

PBS listing for weight management GLP-1 drugs is under active policy consideration, but "considering" means exactly that. The Australian Pharmaceutical Benefits Advisory Committee (PBAC) would need to formally evaluate a submission, assess cost-effectiveness, and make a recommendation before any listing occurs. That process takes time and the outcome is not guaranteed.

If listed, the price difference would be significant. PBS co-payments in 2024 sit at roughly $31.60 for general patients and $7.70 for concession card holders, compared to hundreds of dollars per month out of pocket. Access equity is a legitimate public health argument here, given that obesity disproportionately affects lower-income Australians (Australian Institute of Health and Welfare, 2023).

One more thing: supply shortages remain a real constraint. Both semaglutide and tirzepatide have faced global shortages. A PBS listing that dramatically increases demand could worsen availability for type 2 diabetes patients who currently rely on these drugs. That tradeoff is not mentioned in this video and it is worth knowing about.